Shots: 

• The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555- 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients- and is sponsored by the NIAID
• Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the patients participating in the study. DSMB also considered the impact of the ACTIV-3 study pause on ACTIV-2 and did not recommend any changes to that study’s design or enrollment
• Lilly is testing both single Ab therapy- as well as combinations of Abs as potential therapeutics for COVID-19- across two different patient populations in P-II BLAZE-1- P-III BLAZE-2- and ACTIV-2 study. These trials are not affected by the enrollment pause in the ACTIV-3 clinical trial

­ Ref: Eli Lilly | Image: Eli Lilly